Waled Bahaj, MD

Bone Marrow Transplant and Cellular Therapy Physician @ IBMT

[Waled Bahaj, MD @Bahaj_MD]

@AAlloghbi @sghaseer جهود مباركة ماشاء الله

[OncoAlert @OncoAlert]

On June 23, 2025, the FDA granted accelerated approval to datopotamab deruxtecan-dlnk for adults with locally advanced or metastatic EGFR-mutated non-small cell #LungCancer ( #NSCLC ) who have previously received EGFR-directed therapy and platinum-based chemotherapy.

https://t.co/ImeQNI3o69

This approval was based on efficacy data from the TROPION-Lung05 and TROPION-Lung01 trials, which showed an overall response rate of 45% and a median duration of response of 6.5 months in a subgroup of 114 patients.

@ChristianRolfo @GlopesMd @NarjustFlorezMD @StephenVLiu @JackWestMD @bmassutis @Tony_Calles @s_couraud @marinagarassino @peters_solange @UmbertoMalapel1 @g_mountzios @CharuAggarwalMD @christine_lovly @BairdAM
@jillfeldman4 @bensolomon1 @VanitaNoronha @DrSanjayPopat @DrJNaidoo
@MartinReck2 @Latinamd @bmassutis

#OncoAlertAF
@nataliagandur @acampsmalea @BRicciutiMD
@yekeduz_emre @HHorinouchi @FadiHaddad_MD
@Abdallah81MD @FernandoOnco
@ElisaAgostinett @to_be_elizabeth @bavilima @realbowtiedoc @Erman_Akkus @Lucarecco @GaiaGriguolo @JankovicK
@MarioBalsaMD @DrMirallas @GIMedOnc @OscarTahuahua

[Vivek Subbiah, MD @VivekSubbiah]

🚨 Wow! #ASCO25 @ASCO was absolutely massive!
10 @NEJM papers published simultaneously 👉 all practice-changing studies ! 🔬✨🧵 See below for these studies 👇@oncoalert

[Oncology Brothers @OncBrothers]

Day 1 #ASCO25 highlights:

1. Review on recent approvals

2. #BREAKWATER (update): BRAF+ mCRC

3. #CM8HW (update): MSI-H mCRC

4. #DYNAMIC: ctDNA in colon ca

5. #CAIRO6: periOP Rx in peritoneal mets

#OncTwitter @ASCO

1/6

[Vincent Rajkumar @VincentRK]

The most impressive myeloma abstract at #ASCO25

Outstanding longterm efficacy with cilta-cel CAR-T.

5 year survival rate 50%
5 year PFS rate of 33%

Astounding given multi-drug relapsed refractory setting. @PlasmaCellPete @NoopurRajeMD @TomBmt133 @YiLinMDPhD @DMadduri @bhemato @BerdejaJesus

https://t.co/YiHsGhZ3cw

[Suresh Balasubramanian @malignantheme]

Magrolimab once showed promise in TP53-mutated AML, but recent data didn’t meet the mark, and development has been halted. A tough reminder of the challenges in translating early hope into clinical success. #AML https://t.co/RRGbYHjakf

[Waled Bahaj, MD @Bahaj_MD]

@AAlloghbi @sghaseer ماشاء الله ، تستاهل كل خير ومبارك

[Hagop Kantarjian,MD @DrHKantarjian]

First report of the Ph 2 trial of the CLIA regimen in pts w/ R/R #AML: CR/CRi of 49% & median OS of 12 months in pts who received it as 1st salvage rx. Data provides tolerable & effective backbone upon which to build combination strategies @JournalCancer
https://t.co/EHzqqzGLtc

[Inside The Match @Inside_TheMatch]

Hematology Post Doc Research Fellow Job Opening @washumedicine St. Louis, MO
Info/Apply HERE: https://t.co/MAVczqUL9I

Lab Info: https://t.co/lYArxPl4f4
#InsideTheMatch

[Suresh Balasubramanian @malignantheme]

Congratulations @OpsBug @abdulmoiz82! Differential prognostic impact of NPM1-MT AML underscores the need for age-adapted risk stratification models @MDPIOpenAccess @jeffMDMBA @NanjaSushmitha @JulieBoerner2 @CarmeloGurnari @Bahaj_MD @tariqkewan @VisconteValeria

[Waled Bahaj, MD @Bahaj_MD]

@AAlloghbi سعيد بأني وجدت حسابك هنا

كل الحب والإحترام يا صديقي

[NEJM @NEJM]

Original Article: Daratumumab or Active Monitoring for High-Risk Smoldering Multiple Myeloma (AQUILA) https://t.co/XMTnn80k2u

#ASH24 | @ASH_hematology

[Waled Bahaj, MD @Bahaj_MD]

@calliecoombsmd @Ramikomrokji We enjoyed your lecture today as well.

Thank you both

[Waled Bahaj, MD @Bahaj_MD]

@MatthewHoMD @Dr_AmerZeidan @ZhuoerXie @NeelNabar @n_gangat Great,
I think myeloid sarcoma names has been changed to extra medullary

[Hagop Kantarjian,MD @DrHKantarjian]

NGS MRD (clonoSEQ) is the most sensitive and specific MRD assay in Ph+ #ALL. Therapeutic decision-making should be based on NGS rather than PCR for BCR::ABL1
@NicholasShortMD of @MDAndersonNews #Leukemia
https://t.co/rlZ0aMlGll
#leusm

[Yale Hematology Oncology Fellows @YaleHemOnc]

Sensational multicenter collaborative work presented by Yale fellow @tariqkewan on the clinical implications of tp53 mutation in patients with MDS!! @YaleCancer @Dr_AmerZeidan #ASH23

[Rami komrokji @Ramikomrokji]

Honored to be co-senior author on Imetelstat for lower-risk MDS The Lancet manuscript https://t.co/V6HgddJyIy collaborative effort w great colleagues , hope next rx to approve for MDS. @Dr_AmerZeidan @UwePlatzbecker @Santin13Valeria @MikkaelSekeres @madanatyazan @madicamp

[Yazan Madanat, MD @madanatyazan]

Proud Moment 🎊🎊 Honored to take part of @TheLancet publication along with brilliant #MDS gurus around the world 🌎 looking forward to seeing #Imetelstat become an option for patients with LR-MDS! @utswcancer @UTSWNews @UTSWInternalMed

[Waled Bahaj, MD @Bahaj_MD]

Finally

@VisconteValeria @tariqkewan @HemeOncUofl @CarmeloGurnari @M_Zawit @madanatyazan @md_bat

https://t.co/a4gpbwkLXO

[Vincent Rajkumar @VincentRK]

I’m at the point where I will rather quit than do @ABIMcert Longitudinal Knowledge Assessment (LKA) and try to keep ABIM certification active.

It’s interfering with patient care and research for me. And I’m getting the myeloma questions wrong. Useless.
@Rfonsi1 #MedTwitter